These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 10222349)

  • 1. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.
    Gion M; Mione R; Leon AE; Dittadi R
    Clin Chem; 1999 May; 45(5):630-7. PubMed ID: 10222349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases.
    Gion M; Mione R; Leon AE; Lüftner D; Molina R; Possinger K; Robertson JF
    Eur J Cancer; 2001 Feb; 37(3):355-63. PubMed ID: 11239757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
    Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
    Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
    Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
    Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalization of Elevated Tumor Marker CA27-29 After Bilateral Lung Transplantation in a Patient With Breast Cancer and Idiopathic Pulmonary Fibrosis.
    Copur MS; Wurdeman JM; Nelson D; Ramaekers R; Gauchan D; Crockett D
    Oncol Res; 2018 Apr; 26(3):515-518. PubMed ID: 29229020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.
    Rack B; Jückstock J; Trapp E; Weissenbacher T; Alunni-Fabbroni M; Schramm A; Widschwendter P; Lato K; Zwingers T; Lorenz R; Tesch H; Schneeweiss A; Fasching P; Mahner S; Beckmann MW; Lichtenegger W; Janni W;
    Tumour Biol; 2016 Oct; 37(10):13769-13775. PubMed ID: 27481512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
    Hepp P; Andergassen U; Jäger B; Trapp E; Alunni-Fabbroni M; Friedl TW; Hecker N; Lorenz R; Fasching P; Schneeweiss A; Fehm T; Janni W; Rack B
    Anticancer Res; 2016 Sep; 36(9):4771-6. PubMed ID: 27630326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
    Chen C; Chen Q; Dong Y; Liu X
    Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
    Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
    J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.
    Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H
    Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
    Park BJ; Cha MK; Kim IH
    BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.
    Gion M; Plebani M; Mione R; Penzo C; Meo S; Burlina A
    Br J Cancer; 1994 Apr; 69(4):721-5. PubMed ID: 8142260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of MUC1 in breast cancer patients. A method comparison study.
    Bon GG; van Kamp GJ; Verstraeten RA; von Mensdorff-Pouilly S; Hilgers J; Kenemans P
    Eur J Obstet Gynecol Reprod Biol; 1999 Mar; 83(1):67-75. PubMed ID: 10221613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer.
    Nisman B; Maimon O; Allweis T; Kadouri L; Maly B; Hamburger T; Peretz T
    Anticancer Res; 2013 Jan; 33(1):293-9. PubMed ID: 23267160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the BT-1 serum assay for breast cancer.
    Whitehurst MM; Aldenderfer PH; Sooy MM; Strelkauskas AJ
    Hum Antibodies; 1999; 9(3):155-60. PubMed ID: 10690628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.